For the quarter ending 2026-03-31, TCRX had -$24,349K decrease in cash & cash equivalents over the period. -$24,349K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -28,666 | -22,977 | -35,710 | -71,079 |
| Depreciation expense | 693 | 723 | 767 | 1,376 |
| Accretion of marketable securities | - | -55 | -291 | -2,063 |
| Non-cash interest expense related to loan payable | - | 462 | - | - |
| Non-cash interest expense related to note payable | -222 | - | 118 | 224 |
| Stock-based compensation | 2,465 | 2,008 | 3,011 | 6,687 |
| Prepaid expenses and other assets | -126 | 903 | -867 | 489 |
| Right-of-use assets and lease liabilities, net | 16 | 91 | 463 | 2,355 |
| Accounts payable | 1,045 | -5,067 | 1,933 | 123 |
| Accrued expense and other liabilities | 904 | -3,375 | -1,110 | -2,741 |
| Deferred revenue | -982 | -2,567 | -2,512 | -5,246 |
| Net cash used in operating activities | -24,279 | -32,002 | -32,464 | -70,853 |
| Purchases of marketable securities | - | 0 | -1 | 87,472 |
| Proceeds from maturities of marketable securities | - | 15,000 | 34,000 | 152,250 |
| Purchases of property and equipment | 70 | 171 | 1,425 | 2,811 |
| Net cash provided by (used in) investing activities | -70 | 14,829 | 32,576 | 61,967 |
| Issuance of common stock under employee stock purchase plan | - | 73 | 0 | 191 |
| Cash paid for debt issuance costs | - | 0 | 0 | 400 |
| Cash paid for financing costs | - | 0 | 0 | 200 |
| Net cash provided by (used in) financing activities | - | 73 | 0 | -409 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -24,349 | -17,100 | 112 | -9,295 |
| Cash, cash equivalents, and restricted cash - beginning of period | 157,437 | 174,537 | 183,720 | - |
| Cash, cash equivalents, and restricted cash - end of period | 133,088 | 157,437 | 174,537 | - |
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)